Ethos Laboratories has launched the new fingerstick self-blood collection kit, Tru-Immune, for its Covid-19 neutralising antibody test.
The kit provides quantitative data regarding the viral blocking efficacy of neutralising antibodies.
Individuals can use the kit to measure their current immunity levels against Covid-19 safely, rapidly and efficiently in real-time with less pain.
Additionally, it will help people monitor their neutralising antibody level and reduce the chances to get infected.
The Tru-Immune uses a simple drop of capillary blood from the patients’ fingertip, which will be returned to Ethos through prepaid and priority postage. It delivers the results in 48 hours electronically.
Ethos Laboratories CEO Brian Kincaid said: “As we enter year three of the Covid-19 global pandemic, the question is no longer, ‘Do I have Covid-19 antibodies?’ Instead, people are asking themselves, ‘What level of protective immunity do I have against future infection and do I need a vaccine booster?’ These questions can now be answered with Tru-Immune.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The Covid-19 neutralising antibody tests will provide information regarding the immunity levels against the disease in the individual.
This will help the healthcare provider to make decisions regarding vaccination and booster schedules.
Ethos noted that the neutralising antibody assays like Tru-Immune are expected to become the assay of choice to record natural immunity in states, where employers need proof to get exemption from mandates with regard to vaccines.
In April, Ethos introduced a new molecular test to detect key virus strains of SARS-CoV-2, including the UK (B.1.1.7), South Africa (B.1.351) and Brazil (P.1) variants.